Chegando aos cinemas nesta quinta-feira (28/05), Backrooms: Um No-Lugar e em sesses especiais de pr-estreia hoje, o aguardadssimo filme de estreia no cinema de Kane Parsons, um jovem britnico-americano que vai completar 21 anos s no ms que vem, mas que comeou a desenvolver esse universo em 2021, quando tinha apenas 16 anos, em seu canal no YouTube
The key differences are subtle
Mechanism of Action (MOA): Inhibit the DPP-4 enzyme, preventing the breakdown of endogenous GLP-1, leading to: Glucose-dependent insulin secretion Glucose-dependent glucagon secretion Efficacy: HbA1c reduction: 0.6%0.8% Primarily reduces postprandial glucose Common Dosing: Sitagliptin (Januvia): 100 mg once daily (dose adjustment required in renal impairment) Saxagliptin (Onglyza): 5 mg once daily ( dose in renal impairment) Linagliptin (Tradjenta): 5 mg once daily (no renal or hepatic dose adjustment) Alogliptin (Nesina): 25 mg once daily ( dose in renal impairment) Adverse Effects: Generally placebo-like URTI, headache, mild GI upset Advantages: Weight neutral Suitable for patients with renal impairment (with dose adjustment) Well-tolerated Possible -cellsparing effect Disadvantages: Risk of acute pancreatitis Joint pain Saxagliptin & alogliptin: potential risk of heart failure Precautions: History of pancreatitis Not recommended in DKA Not indicated in Type 1 Diabetes Monitor for heart failure (saxagliptin, alogliptin) #DPP4Inhibitors #Type2Diabetes #ClinicalPharmacy #Pharmacology #MedicationSafety #DiabetesCare #Endocrinology #PharmacyEducation #HealthcareProfessionals To view or add a comment, sign in 3,206 followers
But when we think about risk and benefit, the risk is if youve got low-grade inflammation, youve got early signs of cancer happening, are you going to overload that pathway and promote that cancer to grow bigger, faster? Taylor said
Over 55 years in peptide science, from early neuropeptide work
Gyires K, Knoll J
